The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

Also called NCT05042973

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 165 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05042973
Other papers using this trial's data
  • The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial Cardiovascular diabetology, 2026-06-12 DOI, PubMed 42286641, PMC13483855 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05042973. Randomized; quadruple masking; primary purpose prevention. Start 2021-09-02 (actual); primary completion 2025-01-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
Condition
Obesity
Condition
Heart Failure
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
Jacob Moller (class: other)
Collaborator
Danish Heart Foundation (class: other)
Collaborator
Herlev and Gentofte Hospital (class: other)
Collaborator
University Hospital Bispebjerg and Frederiksberg (class: other)
Collaborator
Hillerod Hospital, Denmark (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)

Record details

Record id
cardio:ct-nct05042973
Content hash
7099103cce4a30e5e7bc6b6a8007345ce877a865cb5538839310492ff9ffffe8